Please assess the completion status of the following clinical trial:

Trial Title: Treating Chronic Insomnia in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients aged 21-60 years old~* Have a negative serum or urine pregnancy test for women of child-bearing potential~* Have a three-month or longer history of insomnia~* Self-report \< 6.5 hours of total sleep time, in addition to a sleep efficiency of less than 85%, averaged over two weeks of screening~* A score of less than 60 on the Zung Self-Rating Depression Scale~* Self-report bedtimes that do not vary by more than two hours on five nights per week~* Have completed chemotherapy for breast cancer less than two years prior to study drug administration~* Have completed chemotherapy for breast cancer for at least two months prior to screening visit~* Patients that are receiving Herceptin are eligible for study enrollment~* Have completed radiation therapy for breast cancer for at least two months prior to screening visit~* ECOG (Eastern Cooperative Oncology Group)score of 0-1~* Be able to read, understand, and provide written informed consent before enrolling in the study~* Must be willing to comply with all study visits and comply with daily phone calls to the IVRS throughout the study~* Agree to participate for the entire study period (about two months)~Exclusion Criteria:~* Metastatic disease~* Pregnant or lactating female~* Self-reports typical consumption of more than five alcoholic beverages on a single day or greater than 14 alcoholic beverages weekly~* Self-reports use of products containing nicotine of greater than 15 cigarettes daily or cannot avoid products containing nicotine during sleep periods~* Current use of any of the following medications, and cannot discontinue these medications for the duration of the study: Hypnotic medication, Anti-convulsants, Anxiolytics, Narcotic analgesics, Medications or supplements containing Melatonin, Ketaconazole and Fluconazole~* Currently taking fluvoxamine, brand name Luvox~* Have symptoms consistent with the diagnosis of any other sleep disorder other than insomnia (e.g. obstructive sleep apnea, narcolepsy, restless legs syndrome)~* Currently on night or rotating shift work~* Self-reports habitual napping of greater than one hour accumulated sleep on 4 or more days per week~* Has a psychiatric illness that interferes with normal sleep-wake function (e.g. major depression, post-traumatic stress disorder)~* A score of 60 or greater on the Zung Self-Rating Depression Scale~* Has current unstable medical disorder, such as symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, or other serious medical condition as determined by the Investigator

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Placebo) (Type: PLACEBO_COMPARATOR): Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
- 2 (Ramelteon) (Type: ACTIVE_COMPARATOR): Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues